a549 lung cancer cells (ATCC)
Structured Review

A549 Lung Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 35502 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/a549 lung cancer cells/product/ATCC
Average 99 stars, based on 35502 article reviews
Images
1) Product Images from "Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer"
Article Title: Deciphering the CAF-LCN2 axis: Key to overcoming anti-PD-L1 immunotherapy resistance in lung cancer
Journal: International Journal of Molecular Medicine
doi: 10.3892/ijmm.2026.5735
Figure Legend Snippet: Impact of CAFs on lung cancer cell resistance to anti-PD-L1 immunotherapy. (A) Diagram outlining the influence of CAFs on the resistance of lung cancer cells to anti-PD-L1 immunotherapy. (B) Cell Counting Kit-8 assay measuring the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. N-A549. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay assessing the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL labeling experiment detecting the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI staining in blue fluorescence. (F) Expression of LCN2 mRNA in A549 cells cultured with CM from NFs and CAFs. (G) Protein expression of LCN2 in A549 cells cultured with CM from NFs and CAFs. *P<0.05, **P<0.01 and ***P<0.001. All cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B) and unpaired two-tailed Student's t-test was used for (C-G). LCN2, lipocalin 2; CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; NFs, normal fibroblasts; CM, conditioned medium; ns, not significant (P>0.05).
Techniques Used: Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Expressing, Cell Culture, Two Tailed Test
Figure Legend Snippet: Impact of CAFs on anti-PD-L1 immunotherapy resistance in lung cancer cells via LCN2 expression. (A) Simplified flowchart depicting how CAFs influence anti-PD-L1 immunotherapy resistance in lung cancer cells through LCN2 expression. (B) Cell Counting Kit-8 assay assessing the sensitivity of A549 cells to anti-PD-L1 treatment. *P<0.05, **P<0.01 and ***P<0.001 vs. C-sh-NC. (C) EdU labeling experiment evaluating the proliferative capacity of A549 cells (scale bar, 25 µm), with EdU labeled in green fluorescence and DAPI in blue fluorescence. (D) Transwell assay investigating the invasive ability of A549 cells (scale bar, 50 µm). (E) TUNEL staining analyzing the apoptotic status of A549 cells (scale bar, 25 µm), with TUNEL staining in green fluorescence and DAPI in blue fluorescence. (F) Measurement of intracellular Fe 2+ and ROS levels (scale bar, 25 µm); *P<0.05, **P<0.01 and ***P<0.001; all cell experiments were conducted in triplicate. One-way ANOVA with Tukey's multiple comparisons test was used for (B-F). CAFs, cancer-associated fibroblasts; PD-L1, programmed death-ligand 1; ROS, reactive oxygen species; sh-, short hairpin; NC, negative control; Fe 2+ , iron; ns, not significant (P>0.05).
Techniques Used: Expressing, Cell Counting, Labeling, Fluorescence, Transwell Assay, TUNEL Assay, Staining, Negative Control

